Welcome to our dedicated page for BioNTech news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BioNTech stock.
BioNTech SE reports recurring developments as a Germany-based biotechnology company whose ADSs trade on Nasdaq. Company news centers on oncology pipeline progress across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies, including lung cancer programs such as pumitamig and gotistobart, as well as COVID-19 vaccine activity tied to its commercial vaccine franchise.
Updates also cover quarterly and annual financial results, research and development spending, corporate presentations, capital allocation actions such as ADS repurchase authorizations, and shareholder meeting or governance matters. BioNTech news frequently links clinical data, partnership activity and operating priorities to its broader objective of building a multi-product biotechnology business.
On June 10, 2021, Pfizer and BioNTech announced a deal with the U.S. government to supply 500 million doses of their COVID-19 vaccine at a not-for-profit price. The agreement includes 200 million doses in 2021 and 300 million doses in the first half of 2022, aimed at low- and middle-income countries via the COVAX Facility. This initiative is part of their commitment to provide two billion doses globally over 18 months. The deliveries will support equitable vaccine access, with production centered in U.S. facilities.
Pfizer (PFE) and BioNTech (BNTX) announced a plan to provide 500 million COVID-19 vaccine doses to the U.S. government at a not-for-profit price, aimed at supporting global vaccination efforts. This includes 200 million doses by the end of 2021 and 300 million in early 2022. The U.S. government will donate these doses to low- and lower-middle-income countries through COVAX. Pfizer and BioNTech aim to produce up to 3 billion doses in 2021, enhancing their supply chain capabilities. Deliveries will begin in August 2021.
Pfizer and BioNTech announced an expansion of the Conditional Marketing Authorization (CMA) for COMIRNATY® in the EU to include adolescents aged 12 to 15. This follows a favorable opinion from the EMA's CHMP. The CMA is now valid across all 27 EU member states. Based on a Phase 3 trial of 2,260 participants, COMIRNATY® showed 100% efficacy in this age group with a favorable safety profile. Pfizer and BioNTech also plan to submit for Emergency Use Authorization for younger age cohorts later this year.
Summary not available.
Pfizer and BioNTech have signed a new agreement with Turkey’s Ministry of Health to supply an additional 60 million doses of their COVID-19 vaccine, bringing the total to 120 million doses for 2021. This collaboration aims to enhance Turkey’s vaccination efforts against COVID-19. The vaccine is based on BioNTech’s mRNA technology, with both companies committed to public health initiatives. CEO Ugur Sahin emphasized their goal to deliver vaccines globally to combat the pandemic effectively.
Pfizer and BioNTech have entered a new agreement with the European Commission to supply 900 million doses of the COVID-19 vaccine COMIRNATY® to the EU, with an optional additional 900 million doses. This follows a prior commitment of 600 million doses for 2021. Deliveries are set to start in December 2021 and continue into 2023, potentially totaling 2.4 billion doses. Both companies emphasize the importance of ongoing vaccinations due to the continued spread of COVID-19 and are committed to adapting their vaccine for emerging variants.
Pfizer and BioNTech announced a new agreement with the European Commission to supply 900 million doses of their COVID-19 vaccine, COMIRNATY, with an option for an additional 900 million doses. Deliveries are scheduled to begin in December 2021 and continue through 2023. This agreement brings the total commitment to 2.4 billion doses since the pandemic began. The companies emphasize the ongoing need for vaccination as COVID-19 persists and highlight their dedication to adapting the vaccine for emerging variants.
BioNTech announced the appointment of Jens Holstein as the new Chief Financial Officer (CFO), effective July 1, 2021. Holstein brings over 25 years of experience in the pharmaceutical sector, previously serving as CFO at MorphoSys AG. This transition allows Sierk Poetting, the current CFO, to concentrate on his role as Chief Operating Officer (COO). Under Poetting's leadership, BioNTech expanded significantly, growing from 300 to over 2,000 employees. The company aims to leverage Holstein's expertise to accelerate its research pipeline and bolster its global manufacturing capabilities.
BioNTech (BNTX) and Pfizer have received FDA's Emergency Use Authorization for their COVID-19 vaccine for individuals aged 12 to 15, marking it as the first vaccine approved for this group in the U.S.
The decision was based on a Phase 3 trial involving 2,260 participants, demonstrating 100% efficacy and robust antibody responses. The companies have also submitted data to the European Medicines Agency (EMA) and expect further global authorizations soon. Research continues into the vaccine's effectiveness in younger children, with data submissions anticipated in September.
Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) announced that the FDA has expanded the Emergency Use Authorization (EUA) for their COVID-19 vaccine to include individuals aged 12 to 15, making it the first vaccine authorized for this age group in the U.S. This decision follows a Phase 3 trial with 2,260 participants showing 100% efficacy and good tolerance of the vaccine. Monitoring for long-term safety will continue for two years post-vaccination. The CDC's Advisory Committee will shortly discuss recommendations for this age group.